Clinical Trial Update: Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

View source ↗

Summary

This clinical trial is evaluating ribociclib in combination with adjuvant endocrine therapy for patients with early high-risk HR+/HER2- breast cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Breast Cancer | Status: RECRUITING